Patented multivalent RNAi platform for multi-gene suppression and viral treatment
HQ Country
Seattle, United States
Employees
1-10
Founded
2008
HQ State/Province
Washington
HQ Full Address
Seattle, Washington, United States
Product Features & Capabilities
Multivalent RNAi trigger (MV-RNA) for multi-gene suppression
Self-forming RNA core (40 nm spheres) with targeted gene silencing
Programmable particle shells using aptamer-driven proteins for tissue-specific delivery
AmpliVIR RNA for SARS-2 self-inactivation
RNA nanoparticle formulations for intracellular delivery
Other Considerations
Pivoting research toward SARS-2 treatment with AmpliVIR RNA; Patented multivalent RNAi platform; Focus on programmable nanoparticle delivery; Early-stage development in RNA delivery and biopharmaceuticals; Research collaboration opportunities with scientists and institutions
Find more companies like Halo-Bio RNAi Therapeutics